Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Molecular Diagnostics Moves Into Prostate Cancer

Executive Summary

While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.


Related Content

Claims And Counterclaims Abound In Highly Competitive Breast Cancer Genomics Market
Medical Device Patents Surging, Industry Players Forecast The Future
Diagnostic Companies Rush To Test Formerly Off-Limit Genes
Myriad Gets Mixed Decision in Supreme Court; Biotech Industry Fears Fallout
Lab-Developed Test Regs In Spotlight With Citizen Petition, Hamburg Speech
Molecular Dx Labs’ Concerns Shift To Coverage Issues With Release Of Interim Medicare Payment Amounts
The Clinical Laboratory Of The Future: Can Technology Fill The Gaps?
Wireless Technology And The Rise Of “Anywhere” Monitoring
Task Force’s PSA Proposal Prompts Calls For More Research On Prostate Cancer Diagnostics
In Vitro Diagnostics: The Quest for Growth


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts